Reviewed by Kate Anderton, B.Sc. (Editor) Feb 4 2020
In a new paper published Feb. 4 in JAMA , Mayo Clinic researchers describe the benefits of in-home noninvasive ventilation therapy- which includes a type referred to as bilevel positive airway pressure, or BiPAP- for many patients with chronic obstructive pulmonary disease (COPD). The team identified a number of benefits, including reduced mortality, fewer hospital admissions, lower risk of intubation, improved shortness of breath, and fewer emergency department visits.
COPD is a chronic lung disease that makes it difficult to breathe. COPD is the third leading cause of death in the U.S., with more than 15 million people currently living with the disease, according to the American Lung Association.
Many people who have COPD suffer from hypercapnia, the retention of carbon dioxide -- a waste product of metabolism normally expelled by the lungs as a person breathes. This may lead to acute respiratory failure and hospitalization. One treatment for chronic hypercapnia is noninvasive ventilation, or a machine with a mask that helps to improve breathing.
Michael Wilson, M.D., a pulmonary and critical care physician at Mayo Clinic, led the study, which was funded by the Agency for Healthcare Research and Quality under a contract with the Mayo Clinic Evidence-Based Practice Center.
Although there is ample evidence supporting in-hospital use of breathing devices such as BiPAP, until now, we didn't know which benefits may be available when we send people home with a new piece of equipment. There were indications that at-home therapy might be beneficial, but there were conflicting studies and guidelines as to what would be best for our patients." Dr. Michael Wilson, pulmonary and critical care physician at Mayo Clinic
He and his colleagues wanted to determine the best practice, collecting and summarizing all available medical knowledge surrounding the topic.
To that end, the team conducted a meta-analysis, combing all available peer-reviewed and other expert literature for relevant randomized clinical trials and comparative observational studies. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology